UBS Group
VBIO

UBS Group’s Valion Bio VBIO Stock Holding History

UBS Group’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.77K Buy
444
+349
+367% +$7.59K ﹤0.01% 8900
2026
Q1 		$2.1K Sell
95
-691
-88% -$17.7K ﹤0.01% 9359
2025
Q4 		$28.5K Buy
786
+754
+2,356% +$43K ﹤0.01% 7557
2025
Q3 		$2.31K Sell
32
-194
-86% -$16.7K ﹤0.01% 9187
2025
Q2 		$23.5K Buy
+226
New +$24.3K ﹤0.01% 8331
2025
Q1 		– Sell
-129
Closed -$19K – 10727
2024
Q4 		$19K Sell
129
-93
-42% -$10.8K ﹤0.01% 7913
2024
Q3 		$23.6K Sell
222
-35
-14% -$5.28K ﹤0.01% 7274
2024
Q2 		$42.6K Buy
+257
New +$80.9K ﹤0.01% 6823
2024
Q1 		– Sell
-1
Closed -$391 – 10009
2023
Q4 		$391 Buy
+1
New +$719 ﹤0.01% 8689
2023
Q3 		– Sell
-1
Closed -$1.85K – 8701
2023
Q2 		$3.14K Sell
1
-2
-67% -$10.7K ﹤0.01% 7660
2023
Q1 		$20.1K Buy
+3
New +$52.6K ﹤0.01% 7075
2022
Q4 		– Hold
0
– – – 9704
2022
Q3 		– Hold
0
– – – 9068
2022
Q2 		– Hold
0
– – – 9131
2022
Q1 		– Hold
0
– -$18K – 10899
2021
Q4 		– Hold
0
– – – 7991

Other funds holding VBIO

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's VBIO Position: Q2 2026 in Review

UBS Group increased its Valion Bio (VBIO) stake by 367% in Q2 2026, buying an estimated $7.59K and bringing the position to 444 shares worth $5.77K. The position accounts for ﹤0.01% of the portfolio, ranked #8900.

UBS Group first reported a position in VBIO in Q1 2023 and has held it in 11 quarters since. The position peaked at $42.6K in Q2 2024. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2026.

  • UBS Group held 444 shares of Valion Bio worth $5.77K as of Q2 2026.
  • UBS Group bought 349 Valion Bio shares in Q2 2026, an estimated $7.59K.
  • Valion Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8900 holding.
  • UBS Group first reported a position in Valion Bio in Q1 2023 and has held it in 11 quarters since.
  • UBS Group's Valion Bio position peaked at $42.6K in Q2 2024.
  • 11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.